Compare
Intelligent Bio Solutions Inc. vs Tenon Medical, Inc. vs Lucid Diagnostics Inc. vs Cerenome, Inc.
| Latest fiscal year | Intelligent Bio Solutions Inc. INBS | Tenon Medical, Inc. TNON | Lucid Diagnostics Inc. LUCD | Cerenome, Inc. CNSY |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.22M | $3.94M | $4.71M | $5.21M |
| Revenue growth (YoY) | +38.1% | +20.4% | +8.3% | -10.5% |
| Gross margin | 48.6% | 59.8% | -41.7% (computed) | n/a |
| Operating margin | -299.1% | -324.3% | n/m | -293.5% |
| Net margin | -294.9% | -318.4% | n/m | -429.4% |
| Net income | -$12.43M | -$12.56M | -$58.01M | -$22.39M |
| EPS (Diluted) | -$8.44 | -$1.70 | n/a | -$0.29 |
| Operating cash flow | -$11.93M | -$10.74M | -$46.48M | -$20.77M |
| Free cash flow | -$12.05M | -$11.02M | -$46.68M | -$20.84M |
| Cash & equivalents | $3.99M | $3.76M | n/a | $4.26M |
| Total assets | $11.94M | $10.76M | $40.45M | $16.32M |
| Total liabilities | $6.65M | $5.72M | $29.51M | $12.33M |
| Shareholders' equity | $5.51M | $5.04M | $10.94M | $4.00M |
| Return on year-end equity | -225.6% | -249.1% | -530.4% | -560.2% |
| Shares outstanding | 2.91M | 10.85M | 131.10M | 138.68M |
Revenue, most recent five fiscal years
| Fiscal year | Intelligent Bio Solutions Inc. | Tenon Medical, Inc. | Lucid Diagnostics Inc. | Cerenome, Inc. |
|---|---|---|---|---|
| Latest | $4.22M Ended 2026-06-30 | $3.94M Ended 2025-12-31 | $4.71M Ended 2025-12-31 | $5.21M Ended 2025-12-31 |
| 1 year earlier | $3.05M Ended 2025-06-30 | $3.28M Ended 2024-12-31 | $4.35M Ended 2024-12-31 | $5.82M Ended 2024-12-31 |
| 2 years earlier | $3.11M Ended 2024-06-30 | $2.93M Ended 2023-12-31 | $2.43M Ended 2023-12-31 | $4.91M Ended 2023-12-31 |
| 3 years earlier | $1.26M Ended 2023-06-30 | $691.0K Ended 2022-12-31 | $377.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $437.1K Ended 2022-06-30 | $160.0K Ended 2021-12-31 | $500.0K Ended 2021-12-31 | n/a |